Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Neutral

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Protara Therapeutics, Inc. Common Stock (TARA)

Biological Products, (no Disgnostic Substances)

http://www.protaratx.com

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/10/2020

Market Cap

42,909,984

Shares Outstanding

11,370,000

Weighted SO

11,364,903

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

VCNX --.--%

MNPR --.--%

MIRO --.--%

SRZN --.--%

IKNA --.--%

XLO --.--%

SRRK --.--%

VACC --.--%

Beta

1.8560

Last Div

0.0000

Range

1.04-5.24

Chg

0.0300

Avg Vol

193459

Mkt Cap

42909984

Exch

NASDAQ

Country

US

Phone

646 844 0337

DCF Diff

-0.9610

DCF

3.0110

Div Yield

0.0000

P/S

35.5215

EV Multiple

0.9479

P/FV

0.4798

Div Yield %

0.0000

P/E

-1.0854

PEG

-0.0285

Payout

-0.0003

Current Ratio

16.3268

Quick Ratio

16.3268

Cash Ratio

15.8607

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1330.3289

CCC

-1330.3289

Gross Margin

0.6854

Op Margin

-36.6333

Pretax Margin

-33.6829

Net Margin

-33.6829

Eff Tax Rate

-0.0387

ROA

-0.4003

ROE

-0.5503

ROCE

-0.4610

NI/EBT

1.0000

EBT/EBIT

0.9195

EBIT/Rev

-36.6333

Debt Ratio

0.0490

D/E

0.0541

LT Debt/Cap

0.0411

Total Debt/Cap

0.0514

Int Coverage

-64.4148

CF/Debt

-6.6868

Equity Multi

1.1043

Rec Turnover

0.0000

Pay Turnover

0.2744

Inv Turnover

0.0000

FA Turnover

0.2029

Asset Turnover

0.0119

OCF/Share

-1.5696

FCF/Share

-1.5739

Cash/Share

4.2189

OCF/Sales

-27.5886

FCF/OCF

1.0028

CF Coverage

-6.6868

ST Coverage

-32.2000

CapEx Coverage

-362.2500

Div&CapEx Cov

-317.4000

P/BV

0.4798

P/B

0.4798

P/S

35.5215

P/E

-1.0854

P/FCF

-1.2840

P/OCF

-1.3252

P/CF

-1.3252

PEG

-0.0285

P/S

35.5215

EV Multiple

0.9479

P/FV

0.4798

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 10, 04:35 Protara Announces Pricing of $100 Million Public Offering GlobeNewswire Inc. Nov 15, 22:52 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology GlobeNewswire Inc. Nov 30, 08:30 Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Revenue Product Segmentation